Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 319

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 319
---
, 2022, 2023 and 2024, all IFRS that the IASB had published and that are mandatory are the same as those endorsed by the EU and mandatory in the EU. As a result, the Consolidated Financial Statements comply with IFRS Accounting Standards as published by the IASB and as adopted by the EU.

IFRS include IFRS Accounting Standards (IFRS), International Accounting Standards (“IAS”), as well as the interpretations issued by the Standing Interpretations Committee (“ SIC”), and the International Financial Reporting Interpretations Committee (“IFRIC”). The main accounting methods used to prepare the Consolidated Financial Statements are described below. These methods were used for all periods presented.

F-20

c)Recently issued accounting standards and interpretations

Application of the following new and amended standards is mandatory for the first time for the financial period beginning on January 1, 2024 and, as such, they have been adopted by the Company:

• Amendments to IAS 1: Classification of Liabilities

• Amendments to IAS 7 and IFRS 7: Supplier Financing Arrangements

• Amendments to IFRS 16: Leaseback Liabilities

These amended standards had no impact on the consolidated financial statements.

The following new standards, amendments to existing standards and interpretations have been published but are not applicable in 2024 or have not yet been adopted by the European Union, and have not been applied early:

• IFRS 18 : Presentation of financial statements;

• Amendment to IFRS 9 : Classification and Measurement of Financial Instruments;

• Amendment to IAS 21 : Lack of Exchangeability;

• Amendments to IFRS 7 and IFRS 9: Clarification on Nature-dependent electricity contracts

These standards have not been applied early. Impact studies relating to the application of IFRS 18 and the IFRS 9 Amendment on the classification of financial instruments are in progress.

The accounting rules and valuation principles used for the financial statements at 31 December 2024 are identical to those used for the previous comparative year.

d)Change in accounting policies

There has been no change in accounting policies for any of the years presented.

e)Translation of transactions denominated in foreign currency

Pursuant to IAS 21 The effects of changes in foreign exchange rates, transactions performed by consolidated entities in currencies other than their functional currency are translated at the prevailing exchange rate on the transaction date.

Trade receivables and payables and liabilities denominated